Clinical Effects of the Unani Medicine Formulations Majoon and Tila Baras-e-Aswad on Plaque Psoriasis: A Single-Arm Clinical Study.

IF 1.9 4区医学 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE

Alternative therapies in health and medicine Pub Date : 2025-01-01

Abdul Mobeen, Faisel Manzoor

{"title":"Clinical Effects of the Unani Medicine Formulations Majoon and Tila Baras-e-Aswad on Plaque Psoriasis: A Single-Arm Clinical Study.","authors":"Abdul Mobeen, Faisel Manzoor","doi":"","DOIUrl":null,"url":null,"abstract":"Background: Psoriasis is a chronic, autoimmune, T-cell-mediated inflammatory disease with an \"onset-remission-recurrence\" pattern, and is managed symptomatically, therefore the need for treatment is usually lifelong.Primary study objective: This study aimed to evaluate the efficacy of Majoon and Tila Baras-e-Aswad, two combination formulations, consisting of herbal, mineral, and animal drugs (antioxidants, anti-psoriatic, antihistaminic, antipruritic, and skin protection with healing activities), prescribed for the treatment of Baras-e-Aswad, having a plaque psoriasis-like diagnosis in Unani medicine.Methods/design: Open-label single-arm and single-center clinical study with pre-and post-treatment analysis.Setting: Conducted in National Institute of Unani Medicine (NIUM) Hospital, Bangalore, India.Participants: A total of 36 patients with plaque psoriasis with mild to moderate severity and aged 18-60 were included.Interventions: The intervention formulation Majoon 10 g orally and Tila Baras-e-Aswad topically was given for 45 days. Primary Outcome Measures: Evaluation of prognosis with averaged PASI (Psoriasis Area and Severity Index) (EPAP) and dermatology life quality index (DLQI) were the outcome of the study and analyzed per protocol.Results: The data analysis of 30 patients who completed the study showed a statistically significant result in the EPAP scores (P < .05), which reduced from 1112.57 ± 988.45 at baseline to 1108.95 ± 988.87, 1107.71 ± 988.52, and 1105.57 ± 988.76 on 15th, 30th, and 45th day respectively. DLQI score reduced significantly (P < .05) from 18.60 ± 2.72 at baseline to 15.20 ± 2.90, 10.76 ± 2.07, and 8.00 ± 2.43 on 15th, 30th, and 45th day respectively. The test drugs were found to be tolerable without any adverse effects.Conclusion: This study highlights the positive effect of Majoon and Tila Baras-e-Aswad combination formulation on the clinical efficacy, quality of life, and short-term prognosis in chronic plaque psoriasis patients, providing valuable insights for further research in a well-designed study.","PeriodicalId":7571,"journal":{"name":"Alternative therapies in health and medicine","volume":" ","pages":"22-27"},"PeriodicalIF":1.9000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alternative therapies in health and medicine","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Psoriasis is a chronic, autoimmune, T-cell-mediated inflammatory disease with an "onset-remission-recurrence" pattern, and is managed symptomatically, therefore the need for treatment is usually lifelong.

Primary study objective: This study aimed to evaluate the efficacy of Majoon and Tila Baras-e-Aswad, two combination formulations, consisting of herbal, mineral, and animal drugs (antioxidants, anti-psoriatic, antihistaminic, antipruritic, and skin protection with healing activities), prescribed for the treatment of Baras-e-Aswad, having a plaque psoriasis-like diagnosis in Unani medicine.

Methods/design: Open-label single-arm and single-center clinical study with pre-and post-treatment analysis.

Setting: Conducted in National Institute of Unani Medicine (NIUM) Hospital, Bangalore, India.

Participants: A total of 36 patients with plaque psoriasis with mild to moderate severity and aged 18-60 were included.

Interventions: The intervention formulation Majoon 10 g orally and Tila Baras-e-Aswad topically was given for 45 days. Primary Outcome Measures: Evaluation of prognosis with averaged PASI (Psoriasis Area and Severity Index) (EPAP) and dermatology life quality index (DLQI) were the outcome of the study and analyzed per protocol.

Results: The data analysis of 30 patients who completed the study showed a statistically significant result in the EPAP scores (P < .05), which reduced from 1112.57 ± 988.45 at baseline to 1108.95 ± 988.87, 1107.71 ± 988.52, and 1105.57 ± 988.76 on 15th, 30th, and 45th day respectively. DLQI score reduced significantly (P < .05) from 18.60 ± 2.72 at baseline to 15.20 ± 2.90, 10.76 ± 2.07, and 8.00 ± 2.43 on 15th, 30th, and 45th day respectively. The test drugs were found to be tolerable without any adverse effects.

Conclusion: This study highlights the positive effect of Majoon and Tila Baras-e-Aswad combination formulation on the clinical efficacy, quality of life, and short-term prognosis in chronic plaque psoriasis patients, providing valuable insights for further research in a well-designed study.

本刊更多论文

尤那尼药物配方 Majoon 和 Tila Baras-e-Aswad 对斑块状银屑病的临床效果：单臂临床研究。

背景：银屑病是一种慢性、自身免疫性、T细胞介导的炎症性疾病，具有 "发病-缓解-复发 "模式，可对症治疗，因此通常需要终身治疗：本研究旨在评估Majoon和Tila Baras-e-Aswad两种复方制剂的疗效，这两种制剂由草药、矿物质和动物药（抗氧化剂、抗银屑病药、抗组胺药、止痒药和具有治疗活性的皮肤保护药）组成，用于治疗尤那尼医学中诊断为斑块状银屑病的Baras-e-Aswad：方法/设计：开放标签单臂单中心临床研究，进行治疗前后分析：在印度班加罗尔国立尤那尼医学研究所（NIUM）医院进行：共纳入 36 名轻度至中度斑块状银屑病患者，年龄在 18-60 岁之间：干预措施：口服干预配方 Majoon 10 克，外用 Tila Baras-e-Aswad 45 天。主要结果指标：以平均PASI（银屑病面积和严重程度指数）（EPAP）和皮肤病生活质量指数（DLQI）评估预后，并按方案进行分析：对完成研究的 30 名患者进行的数据分析显示，EPAP 评分从基线时的 1112.57 ± 988.45 分分别降至第 15 天、第 30 天和第 45 天的 1108.95 ± 988.87 分、1107.71 ± 988.52 分和 1105.57 ± 988.76 分，差异有统计学意义（P < .05）。DLQI 评分从基线时的 18.60 ± 2.72 显著降至第 15 天、第 30 天和第 45 天的 15.20 ± 2.90、10.76 ± 2.07 和 8.00 ± 2.43（P < .05）。试验结果表明，试验药物均可耐受，无任何不良反应：本研究强调了 Majoon 和 Tila Baras-e-Aswad 复方制剂对慢性斑块型银屑病患者的临床疗效、生活质量和短期预后的积极影响，为设计良好的进一步研究提供了宝贵的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alternative therapies in health and medicine INTEGRATIVE & COMPLEMENTARY MEDICINE-

CiteScore

0.90

自引率

0.00%

发文量

219

期刊介绍： Launched in 1995, Alternative Therapies in Health and Medicine has a mission to promote the art and science of integrative medicine and a responsibility to improve public health. We strive to maintain the highest standards of ethical medical journalism independent of special interests that is timely, accurate, and a pleasure to read. We publish original, peer-reviewed scientific articles that provide health care providers with continuing education to promote health, prevent illness, and treat disease. Alternative Therapies in Health and Medicine was the first journal in this field to be indexed in the National Library of Medicine. In 2006, 2007, and 2008, ATHM had the highest impact factor ranking of any independently published peer-reviewed CAM journal in the United States—meaning that its research articles were cited more frequently than any other journal’s in the field. Alternative Therapies in Health and Medicine does not endorse any particular system or method but promotes the evaluation and appropriate use of all effective therapeutic approaches. Each issue contains a variety of disciplined inquiry methods, from case reports to original scientific research to systematic reviews. The editors encourage the integration of evidence-based emerging therapies with conventional medical practices by licensed health care providers in a way that promotes a comprehensive approach to health care that is focused on wellness, prevention, and healing. Alternative Therapies in Health and Medicine hopes to inform all licensed health care practitioners about developments in fields other than their own and to foster an ongoing debate about the scientific, clinical, historical, legal, political, and cultural issues that affect all of health care.